Haemate

Haemate is a prescription intravenous medication containing human von Willebrand factor as its active ingredient. It is supplied as a von Willebrand factor concentrate used to replace deficient factor in patients with bleeding disorders. The product is marketed in the European Union and is classified as a hemostatic agent. Haemate is administered under medical supervision to support platelet adhesion and stabilize factor VIII activity for therapeutic purposes.

Haemate is indicated for the management of bleeding in patients with specific inherited clotting disorders.

- Replacement therapy for von Willebrand disease (type 1, 2, and 3). - Adjunctive treatment to reduce bleeding during surgery or dental procedures in von Willebrand disease. - Supportive therapy for hemophilia A patients with low factor VIII levels when von Willebrand factor is needed. - Prophylactic use in patients with frequent spontaneous bleeds. - Management of postpartum hemorrhage associated with von Willebrand factor deficiency.

Potential adverse reactions to Haemate have been reported; they vary in frequency and severity.

Common: - Headache, often mild and transient. - Fever or chills occurring shortly after infusion. - Nausea or vomiting, typically resolving without intervention. - Local infusion site reactions such as erythema, swelling, or mild pain.

Serious: - Allergic reactions ranging from rash and urticaria to severe anaphylaxis. - Thromboembolic events, including deep vein thrombosis or pulmonary embolism. - Development of neutralizing antibodies (inhibitors) against von Willebrand factor. - Renal dysfunction or hemolysis observed in rare cases.

Healthcare providers should consider several precautions when prescribing Haemate to ensure safe and effective use.

- Assess patient history for prior allergic reactions to plasma-derived products. - Monitor for signs of thrombosis, especially in patients with risk factors. - Evaluate renal and hepatic function before initiating therapy. - Use caution in pregnant or breastfeeding women; limited safety data are available. - Adjust dosing in patients with known inhibitors to von Willebrand factor. - Avoid use in individuals with uncontrolled hypertension or active infection.

Haemate may interact with other medications; awareness of potential interactions helps minimize adverse outcomes.

Avoid: - Concomitant use of other plasma-derived clotting factor concentrates without medical supervision. - High-dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution: - Antifibrinolytic agents (e.g., tranexamic acid) when combined may enhance clot stability. - Warfarin or other anticoagulants, requiring close monitoring of coagulation parameters. - Desmopressin (DDAVP) if used together, may increase von Willebrand factor levels excessively.